SINTX Technologies earnings beat by $0.10, revenue topped estimates

SINTX Technologies (SINT) reported Q3 EPS of -$0.24, beating estimates by $0.10, with revenue of $2.2M, exceeding expectations of $908K. The stock is down 2.41% over 3 months and 52.21% over 12 months. InvestingPro rates its financial health as 'weak performance.'

Original reporting
Published Nov 5, 2026, 11:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 11:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SINT
Bullish
medium confidence
Mentioned
$SINT
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SINTBullishMed
01

Why it matters

The earnings beat provides a fresh data point that could temporarily lift sentiment, but the company's fundamentals remain fragile.

02

Market read

Earnings beat offers limited trading opportunity for short‑term traders; broader market impact is negligible.

03

What to watch

Weak financial health rating and steep price decline over 12 months suggest underlying challenges.

Relevance 6/10Novelty 6/10Timing: after-hours

Background

SINTX Technologies (NASDAQ:SINT) is a micro‑cap biotech firm with a weak financial health rating and a history of price declines.

Company-level read

Ticker impact

$SINTBullishMedium confidence
Context

Q3 EPS beat by $0.10 and revenue topped estimates, providing fresh earnings data for SINTX Technologies.

Expected impact

likely upward pressure as traders price in the beat

Evidence & confidence

The beat is modest and the company is a micro‑cap, so impact is limited but could spark a brief rally.

Market effects

Minimal; the beat does not materially affect the broader biotech/tech sector.

Limited to U.S. micro‑cap investors.

None

Counterpoint

The beat may be a one‑off and the stock could face downside if guidance is weak.

Key entities

  • SINTX Technologies

    Issuer of the earnings report.

Related articles

$SINTMed

SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization

Sintx Technologies, Inc. (SINT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization Third quarter revenue increases more than tenfold year over year, while operating losses decrease 51% as Company advances commercialization of its proprietary silicon

$SINTMed

SINTX Announces Preliminary $2.2 Million in Q3 Revenue, Exceeding High-End Guidance

Sintx Technologies, Inc. (SINT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SINTX Announces Preliminary $2.2 Million in Q3 Revenue, Exceeding High-End Guidance Third-quarter revenue grows roughly 380% from Q2, driven by stronger-than-expected industrial sales to Fortune 500 customers; Company reiterates Q4 revenue guidance Revenue milestone

$SINTLow

SINTX Technologies Provides Mid-Year 2026 Business Update Highlighting Commercial Execution, Biomaterial Platform Expansion and Strategic Growth Initiatives

Sintx Technologies, Inc. (SINT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SINTX Technologies Provides Mid-Year 2026 Business Update Highlighting Commercial Execution, Biomaterial Platform Expansion and Strategic Growth Initiatives SALT LAKE CITY, Utah – August 11, 2026 – SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a

$SINTLow

Sintx Technologies (NASDAQ:SINT) Given “Buy” Rating at Maxim Group

Maxim Group reiterated a “Buy” rating on Sintx Technologies (NASDAQ:SINT) and set a $6.00 price target, implying 169.66% upside from the prior close, according to Benzinga. Other firms cited include Ascendiant (cut target to $12, Buy), Weiss (sell), and HC Wainwright (Buy, $10). SINT last traded at $2.23. The company reported Q EPS of ($0.70) vs ($0.66) consensus and revenue of $0.38M vs $0.30M.

$WBMedAI 8/10

Alibaba Is Pulling Back From This 10% Dividend Stock

Weibo (WB) missed Q3 revenue and earnings expectations, with advertising revenue from Alibaba (BABA) falling 33%. Shares dropped 4% premarket. GAAP net income fell 88.91%, operating cash flow turned negative, and long-term loans were reclassified as current. The dividend yield is 10.6%, but earnings are declining. CEO Gaofei Wang highlighted AI efforts, but ad budgets remain a concern.